Related Experiment Video
Updated: Jul 1, 2025
Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies
Published on: September 15, 2016
Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology.
Marta Caballero-Ávila1, Cinta Lleixà1, Elba Pascual-Goñi1
1From the Neuromuscular Diseases Unit (M.C.-Á., C.L., E.P.-G., L.M.-A., N.V.-F., C.T.-I., R.C.-V., R.R.-G., E.C.-V., J.T.-S., E.G., M.O., A.V., Á.C., L.L., L.Q.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau, Universitat Autònoma de Barcelona; Neuromuscular Diseases (C.L., R.R.-G., E.C.-V., J.T.-S., E.G., M.O., L.Q.), Centro para la Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid; Department of Immunology (L.M.-M.), Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau, Universitat Autònoma de Barcelona, Spain; UCB Pharma (A.S., L.C., B.D.), Slough; and Retrogenix (Charles River's company) (J.F., J.S., S.D.), United Kingdom.
This study shows a human cell microarray can find autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Potential CIDP-specific antibodies like anti-leukemia-inhibitory factor (LIF) and anti-interferon lambda (IFNL) were identified but require further research.
Area of Science:
- Immunology
- Neuroscience
- Biotechnology
Background:
- Autoantibody discovery in complex autoimmune diseases like CIDP is challenging.
- Existing antigen identification strategies often fail with conformational or post-translationally modified proteins.
- Human membrane and secreted protein microarray technology offers a novel approach.
Purpose of the Study:
- To assess the utility of a human cell microarray for detecting autoantibodies in CIDP.
- To identify novel autoantibodies associated with CIDP.
- To validate identified autoantibodies using multiple methods.
Main Methods:
- Utilized a cell microarray expressing over 5,000 human proteins.
- Validated technology with known autoantibodies in autoimmune nodopathy (AN) samples.
- Screened 8 CIDP serum samples for novel IgG autoantibodies, followed by validation with cell-based assays, ELISA, and immunohistochemistry.
Main Results:
- Detected known autoantibodies (anti-contactin-1, anti-neurofascin-155).
- Identified six novel potential CIDP-associated autoantibodies, including anti-leukemia-inhibitory factor (LIF) and anti-interferon lambda (IFNL1-3).
- Anti-LIF and anti-IFNL antibodies were found in two CIDP patients, not controls, and showed specific staining patterns.
Conclusions:
- Human cell microarray technology is effective for detecting known and discovering novel autoantibodies.
- Potential CIDP-associated autoantibodies (anti-LIF, anti-IFNL3) were identified.
- Further investigation in larger cohorts is needed to confirm the clinical and pathogenic relevance of these novel autoantibodies.
